



Driven by strong desire to relieve pain

A sense of mission gives Terumo its drive

Many people, suffering from diabetes have to inject themselves with insulin every day. Painful injections are difficult not only for the patients to endure but also for their loved ones.

Terumo, driven by our strong desire and the sense of mission as a syringe needle manufacturer, started development of “low-pain needles” to address the situation. After a lot of trial and error, we succeeded in creating the world’s thinnest needle for insulin. This needle was a result of the combination of a number of technologies with the creativity of our associates, who were driven more than anything by the thoughts of seeing the smiles on the faces of the patients who would use it.




Needle for insulin injection

Minimally invasive—Coronary intervention therapies using catheters

Aiming to improve quality of life

Angina pectoris and other types of chest pain may be caused by a narrowing in the coronary artery. In the past, the main treatment option was coronary artery bypass surgery. These days, however, coronary intervention therapy which uses a catheter—a thin tube to which a balloon is attached—to dilate the artery is becoming more common, leading to dramatically shortened hospital stays.

Terumo’s catheter products are used widely around the world in coronary intervention treatment and contribute to the improvement of patients’ overall quality of life.



Coronary intervention therapy using a catheter

For more patient safety and comfort

Terumo is supporting to popularize Transradial Coronary Intervention (TRI) therapy, in which a patient’s coronary artery can be treated via a catheter inserted into the wrist artery. TRI is proven to reduce complications from bleeding and, unlike the trans-femoral approach through the thigh, lets patients get back on their feet and resume their normal activities immediately after the procedure.



Training for techniques used in the treatment

Terumo continues to develop new TRI products as well as providing support for education and training programs to help spread this patient friendly medical procedure.

Continuing to take on challenges to meet the healthcare needs

Left ventricular assist system: Our 12-year dream comes true

Heart failure caused by such diseases as myocardial infarction and cardiomyopathy accounts for a large proportion of deaths around the world and the number of critically ill patients who need heart transplants far exceeds the number of donors. In an effort to save as many lives as possible, we have worked for many years to develop an artificial heart that could be used to assist the functioning of the patient's own heart.

In 2007, Terumo finally launched its magnetically levitated centrifugal left ventricular assist system—the world's first—on the European market.

Although the system is now mainly used as a temporary "bridge" to provide additional time for a patient to wait for a heart transplant, we are also aiming to expand its intended use for prolonged cardiac support.



Left ventricular assist system (LVAS)



The developer (left) and a patient (right) implanted with our LVAS, which allows him to move about

Terumo's continuous development

Our R&D efforts continue to serve up better products. In 1982, Terumo developed the world's first hollow-fiber oxygenator for the efficient exchange of oxygen and carbon dioxide without damaging blood. In 2008, we further evolved the technology and succeeded in developing the smallest oxygenator in the world, which can be used during heart operations performed on newborns and infants.



Envisioning the next step in "people-friendly healthcare"

Smaller, easier-to-use, safer and more reliable—these needs are constantly evolving and transforming. Our mission, underpinned by our determination to provide "people-friendly healthcare," is to respond to these needs.

True to our history of taking on challenge after challenge and braced with a determination that overcomes any setbacks we may encounter, we will continue our efforts to advance healthcare.